Clinical Trials Sponsored by General Therapeutics

Total 22359 results

General Therapeutics

Not yet recruiting

Cell-free Stem Cell-derived Extract Formulation for Knee Osteoarthritis

Osteoarthritis, Knee
Massachusetts General Hospital
TG Therapeutics

Active, not recruiting

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2

United States
Better Therapeutics
Mass General Brigham

Active, not recruiting

A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus (ACTION-DM)

Diabetes Type 2

United States
Massachusetts General Hospital
Blue Note Therapeutics

Terminated

Psychological Mobile App for Patients With AML

Acute Myeloid Leukemia | AML

United States
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors

Solid Tumor, Adult

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

Lymphoma

China
Nova Therapeutics LLC
Chinese PLA General Hospital

Recruiting

CART-PSMA Cells for Advanced Prostate Cancer

Prostate Cancer

China
Chinese PLA General Hospital
UTC Therapeutics Inc.

Recruiting

CD40 Ligand Expressing MSLN-CAR T Cell Therapy in MSLN Positive Advanced/Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

China
Abeona Therapeutics, Inc
Genaera Corporation

Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Diabetic Foot Ulcers

United States
Abeona Therapeutics, Inc
Genaera Corporation

Completed

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Diabetic Foot Ulcers

United States
Help Therapeutics
Central South University

Recruiting

Allogeneic iPSC-derived Cardiomyocyte Therapy in Patients With Worsening Ischemic Heart Failure

Chronic Heart Failure | Ischemic Heart Failure

China
Massachusetts General Hospital
Pfizer; Akcea Therapeutics; Alnylam Pharmaceuticals; Eidos Therapeutics, a BridgeBio...

Recruiting

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF (TTRinHFpEF)

Heart Failure | Amyloidosis | Heart Failure, Diastolic | Transthyretin Amyloidosis

United States
Rapa Therapeutics LLC
Massachusetts General Hospital; Hackensack Meridian Health

Recruiting

RAPA-501 Therapy for ALS

Amyotrophic Lateral Sclerosis

United States
Rapa Therapeutics LLC
Massachusetts General Hospital; Hackensack Meridian Health

Available

RAPA-501 Therapy for ALS EAP

Amyotrophic Lateral Sclerosis

United States
Massachusetts General Hospital
Bristol-Myers Squibb; Leap Therapeutics, Inc.

Terminated

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Biliary Tract Cancer

United States
Merit E. Cudkowicz, MD
Prilenia Therapeutics

Completed

HEALEY ALS Platform Trial - Regimen D Pridopidine

Amyotrophic Lateral Sclerosis

United States
Massachusetts General Hospital
Center for Microbiome Informatics and Therapeutics

Active, not recruiting

Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy

Hepatic Encephalopathy

United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Seventh Medical Center of PLA General Hospital
GeneCradle Therapeutics, Inc

Recruiting

Clinical Exploration of Adeno-associated Virus (AAV) Expressing Human Acid Alpha- Glucosidase (GAA) Gene Therapy for Patients With Infantile-onset Pompe Disease

Infantile-onset Pompe Disease

China
Merit E. Cudkowicz, MD
Seelos Therapeutics, Inc.

Completed

HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose

Amyotrophic Lateral Sclerosis

United States
Merit E. Cudkowicz, MD
Denali Therapeutics Inc.

Enrolling by invitation

HEALEY ALS Platform Trial - Regimen G DNL343

Amyotrophic Lateral Sclerosis

United States
Jeff C. Huffman, MD
BioXcel Therapeutics Inc

Unknown

Dexmedetomidine Sublingual Film for the Management of Agitation in Delirium: Safety and Preliminary Efficacy

Delirium
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada
APRINOIA Therapeutics, LLC

Active, not recruiting

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

Healthy Volunteers | Alzheimer's Disease | Mild Cognitive Impairment Due to Alzheimer's Disease

United States
iCell Gene Therapeutics
The General Hospital of Western Theater Command; Peking University Shenzhen... and other collaborators

Recruiting

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Hematologic Malignancy | Myeloproliferative Neoplasm

China
Universitas Sriwijaya
Dr. Mohammad Hoesin Central General Hospital

Completed

Effectiveness of PRP, Conditioned Medium UC-MSCs Secretome and Hyaluronic Acid for the Treatment of Knee Osteoarthritis

Knee Osteoarthritis

Indonesia
Base Therapeutics (Shanghai) Co., Ltd.
The General Hospital of Eastern Theater Command

Recruiting

Safety and Efficacy of NK510 to Treat NSCLC

NSCLC

China
Northern Therapeutics
Unity Health Toronto; Sir Mortimer B. Davis - Jewish General Hospital

Completed

Pulmonary Hypertension: Assessment of Cell Therapy (PHACeT)

Hypertension, Pulmonary

Canada
Stephane Genevay
University Hospital, Geneva

Terminated

Local Injection Under US Control in GTPS.

Bursitis | Periarthritis

Switzerland
CRISPR Therapeutics AG
ViaCyte

Recruiting

An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Melinta Therapeutics, LLC

Recruiting

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

Gram Positive Bacterial Infections

United States
TenNor Therapeutics Limited

Completed

TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection (P2_ABSSSI)

Gram-Positive Bacterial Infections | Skin and Subcutaneous Tissue Bacterial Infections

United States
CRISPR Therapeutics AG
ViaCyte

Completed

An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D

Glucose Metabolism Disorders | Immune System Diseases | Autoimmune Diseases | Diabetes Mellitus | Endocrine System Diseases | Diabetes Mellitus, Type 1 | Metabolic Disease

Canada

Clinical Trials Sponsored by General Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations